Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study

Gynecologic Oncology

Volumn 123, Issue 1, 2011, Pages 33-36

  Bodnar, Lubomir ^a   Górnas, Maria ^a,b   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b Holy Family Clinic of Gynecology and Obstetrics in Warsaw   (Poland)

Author keywords

Epithelial ovarian cancer; Primary peritoneal carcinoma; Salvage therapy; Sorafenib

Indexed keywords

SORAFENIB;

ACNE; ADULT; AGED; ANEMIA; ARTHRITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EPITHELIAL OVARY CANCER; FEMALE; GINGIVITIS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY PERITONEAL CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PYRIDINES; SALVAGE THERAPY;

EID: 80052604394     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.06.019     Document Type: Article

References (28)

1. D.M. Parkin, F.I. Bray, and S.S. Devesa Cancer burden in the year 2000. The global picture Eur J Cancer 37 2001 S4 S66
2. A. Jemal, R. Siegel, J. Xu, and E. Word Cancer statistics. 2003 CA Cancer J Clin 60 2010 277 300
3. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.S. Dvorak Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 1983 983 985
4. P.J. Paley, K.A. Staskus, K. Gebhard, D. Mohanraj, L.B. Twiggs, and L.F. Carson Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 80 1997 98 106 (Pubitemid 27270925)
5. N. Nishida, H. Yano, and K. Komai Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma Cancer 101 2004 1364 1374 (Pubitemid 39180392)
6. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
7. E. Lierman, I. Lahortiga, and H. Van Miegroet T he ability of sorafenib to inhibit oncogenic PDGFR beta and FLT3 mutants and overcome resistance to other small molecule inhibitors Haematologica 92 2007 27 34 (Pubitemid 46232655)
8. S. Wilhelm, C. Carter, and M. Lynch Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 2006 835 844 (Pubitemid 44480537)
9. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
10. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
11. G.K. Dy, S.L. Hillman, K.M. Rowland Jr., J.R. Molina, P.D. Steen, and D.B. Wender North Central Cancer Treatment Group Study N0326. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326 Cancer 116 2010 5686 5693
12. A. Hauschild, S.S. Agarwala, U. Trefzer, D. Hogg, C. Robert, and P. Hersey Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2009 2823 2830
13. E.T. Lam, M.D. Ringel, R.T. Kloos, T.W. Prior, M.V. Knopp, and J. Liang Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 28 2010 2323 2330
14. C. Elser, L.L. Siu, and E. Winquist Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 2007 3766 3773 (Pubitemid 47372619)
15. R.G. Maki, D.R. D'Adamo, M.L. Keohan, M. Saulle, S.M. Schuetze, and S.D. Undevia Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol 27 2009 3133 3140
16. F. Mc Phillips, P. Mullen, B.P. Monia, A.A. Ritchie, F.A. Dorr, and J.F. Smyth Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer Br J Cancer 85 2001 1753 1758 (Pubitemid 34081523)
17. C. Gianpaolo-Ostravage, C. Carter, and B. Hibner Anti-tumour effcacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumour xenograft models Proc. Am. Assoc. Cancer Res. 42 2001 923
18. S.A. Welch, H.W. Hirte, L. Elit, R.J. Schilder, L. Wang, and K. Macalpine Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium Int J Gynecol Cancer 20 2010 787 789
19. D. Strumberg, A. Awada, H. Hirte, J.W. Clark, S. Seeber, and P. Piccart Schwartz B Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42 2006 548 556 (Pubitemid 43227936)
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. Common Terminology Criteria for Adverse Events, Version 3.0 revised June 10, 2003. National Cancer Institute http://ctep.cancer.gov/forms/CTCAEv3.pdf
22. J. Eng Sample size estimation: how many individuals should be studied? Radiology 227 2003 309 313 (Pubitemid 36514740)
23. D. Matei, R.E. Emerson, and Y.C. Lai Autocrine activation of PDGFR alpha promotes the progression of ovarian cancer Oncogene 25 2006 2060 2069
24. C.A. Boocock, D.S. Charnock-Jones, and A.M. Sharkey Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma J Natl Cancer Inst 87 1995 506 516
25. D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, and S.D. McMeekin Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2007 2811 2818 (Pubitemid 47123191)
26. L. Bodnar, G. Wcislo, A. Nasilowska, K. Szarlej-Wcislo, A. Gasowska-Bodnar, and M. Smoter Salvage therapy with topotecan in heavily pretreated ovarian cancer patients J Cancer Res Clin Oncol 135 2009 815 821
27. D. Matei, M.W. Sill, H.A. Lankes, K. Degeest, R.E. Bristow, and D. Mutch Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial J Clin Oncol 29 2011 69 75
28. N. Matsumura, M. Mandai, T. Okamoto, K. Yamaguch, S. Yamamura, and S. Oura Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling Cancer Sci 101 2010 2658 2663